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Abstract
Background: Human herpesvirus 6 (HHV-6), mostly variant B reactivation in renal transplant patients has been
published by other authors, but the pathogenetic role of HHV-6 variant A has not been clarified. Our aims were to
examine the prevalence of HHV-6, to determine the variants, and to investigate the interaction between HHV-6
viraemia, human cytomegalovirus (HCMV) infection and clinical symptoms.
Methods: Variant-specific HHV-6 nested PCR and quantitative real-time PCR were used to examine blood samples
from renal transplant patients and healthy blood donors for the presence and load of HHV-6 DNA and to
determine the variants. Active HHV-6 infection was proved by RT-PCR, and active HCMV infection was diagnosed
by pp65 antigenaemia test.
Results: HHV-6 viraemia was significantly more frequent in renal transplant patients compared to healthy blood
donors (9/200 vs. 0/200; p = 0.004), while prevalence of HHV-6 latency was not significantly different (13/200 vs.
19/200; p > 0.05). Dominance of variant A was revealed in viraemias (8/9), and the frequency of HHV-6A was
significantly higher in active infections compared with latency in renal transplant patients (8/9 vs. 2/13; p = 0.0015).
Latency was established predominantly by HHV-6B both in renal transplant patients and in healthy blood donors
(11/13 and 18/19). There was no statistical significant difference in occurrence of HCMV and HHV-6 viraemia in
renal transplant patients (7/200 vs. 9/200). Statistical analysis did not reveal interaction between HHV-6 viraemia
and clinical symptoms in our study.
Conclusions: Contrary to previous publications HHV-6A viraemia was found to be predominant in renal transplant
patients. Frequency of variant A was significantly higher in cases of active infection then in latency.
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Background
Immunosuppression associated with renal transplanta-
tion presents a risk for opportunistic infections, reactiva-
tions and reinfections. Human herpesvirus 6 (HHV-6) is
an important pathogen in transplant recipients. HHV-6
is ubiquitous in the population, primary infection occurs
in early childhood after which latency is established and
the seropositivity exceeds 90% [1]. There are two distinct
variants of HHV-6 [2]: variants A and B (HHV-6A,
HHV-6B). Primary infection almost always occurs with
HHV-6B [3], but it is not clarified when HHV-6A infec-
tion takes place. HHV-6 infecti o ni nt r a n s p l a n tp a t i e n t s
may be the result of donor transmission, reactivation of
latent infection in the recipients or reinfection [4]. HHV-
6 reactivation occurs early, 38-60% of the patients are
affected 2-4 weeks after transplantation [5-7], but late
infections up to 2 years has been also described [8,9].
Infection is often asymptomatic [10], but reactivations
can result in fever, rash, thrombocytopenia, leukopenia,
pneumonia, hepatitis, pancreatitis, colitis, encephalitis,
meningoencephalitis, even prolonged bone marrow
suppression [4]. HHV-6 can also modulate the immune
system which can result in spread and persistence of
HHV-6 and can enhance the effects of other infection
[11]. There is increasing evidence for simultaneous reac-
tivation of HHV-6 and HCMV [12-15], an action which
predicts higher risk for severe disease [15]. It is also sug-
gested that HHV-6 reactivation occurs earlier than
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ar o l ei nt h er e a c t i v a t i o no fH C M Vb yi n d u c t i o no f
immunosuppression or by interaction with HCMV. In
peripheral blood samples of renal transplant patients
HHV-6 variant B is more frequently isolated [16,17], but
v a r i a n tAm a yb em o r ev i r u l e n t[ 1 8 ] .T h ea i m so ft h i s
study were to investigate the prevalence of HHV-6 infec-
tion in renal transplant patients at different times after
transplantation, to determine the subtype of HHV-6, and
to examine the possible association of HHV-6 infection
with HCMV reactivation and clinical symptoms.
Results
HHV-6 viraemia
Twelve plasma and white blood cells (WBC) samples (6%)
of 12 renal transplant patients were HHV-6 DNA positive.
Dominance of HHV-6 variant A was revealed (10/12). The
level of HHV-6A DNA in plasma samples ranged from
7.5 × 10
2 to 6 × 10
5 (median 5.9 × 10
3)g e n o m ee q u i v a -
lent/mL (GEq/mL), while the copy number of HHV-6B
genome was below the limit of detection (less then
250 GEq/mL). In WBC samples HHV-6 DNA load ranged
from 5.1 × 10
2 to 2.1 × 10
6 (median 1.8 × 10
3)G E q / 1 . 5
x10
6 cells. Three samples were negative for HHV-6
mRNA, while RT-PCR proved active HHV-6 infection in
nine samples (8 HHV-6A and 1 HHV-6B; Table 1).
Statistical analysis did not reveal significant age differ-
ences between HHV-6 positive (range 17.9-61.7 years;
median 37.8 years) and negative (11.2-68.8 years; median
45.4 years) patients. There was also not significant dif-
ference between the time of sample taking after the
transplantation of HHV-6 positive (range 21 days-13.1
years; median 6.2 years) and negative (range 3 days-19.6
years, median 3.3 years) patients.
Among healthy blood donors HHV-6 DNA, variant A
was detected in both the plasma and WBC of one sam-
ple; 5.8 × 10
3 GEq/1.5 × 10
6 WBC was measured, but
the viral load in plasma was below the limit of detection.
RT-PCR did not confirm active infection (Table 1).
HHV-6 latency
HHV-6 latency was revealed in 13 renal transplant
patients (6.5%; 11 HHV-6B and 2 HHV-6A; Table 1).
HHV-6 DNA was detected only in WBC. HHV-6
mRNA was not found in these samples.
HHV-6 DNA was found in WBC without active HHV-
6 replication in 19 healthy blood donors (9.5%; 18 HHV-
6B and 1 HHV-6A; Table 1).
HCMV reactivation
Seven patients (3.5%) had HCMV reactivation shown by
detection of pp65 antigen in WBC.
Statistical analysis did not show significant age differ-
ences between HCMV positive (range 44.1-61.6 years;
median 55.4 years) and negative (11.2-65.7 years; median
44.8 years) patients. There was also not significant dif-
ference between the time of sample taking after the
transplantation of HCMV positive (range 50 days-15.7
years; median 0.3 years) and negative (range 21 days-
13.1 years, median 6 years) patients.
Simultaneous presence of HCMV and HHV-6 virae-
mia was not detected.
Clinical data
Thirty one patients did not have clinical symptoms;
fever, respiratory and gastrointestinal symptoms were
observed in 169 patients (Table 2). All the patients had
good graft functions at the time of the examination.
Statistical analyses of HHV-6 viraemia and clinical
symptoms did not reveal association between the pre-
sence of virus and the observed clinical symptoms.
Discussion
In this study significantly higher prevalence of HHV-6
viraemia was found among renal transplant patients then
among healthy blood donors (9/200 vs. 0/200; p = 0.004).
The frequency of HHV-6 infection was not significantly
different from the frequency of HCMV reactivation
(9/200 vs. 7/200; p > 0.05). Previous reports have noted
that HHV-6 viraemia was found early, but also late after
transplantation [4,13,14]. Significant difference was not
found between HHV-6 positive and negative patients
regarding the days after transplantation at the time of
sample collection (p > 0.05). HHV-6 is able to establish
latency and integrate into human chromosomes, hence
viral DNA can originate from lysis of cells. The incidence
Table 1 Prevalence of HHV-6 and HHV-6 variants A and B in renal transplant patients and healthy controls
Viraemia Latency
Transplant Healthy Transplant Healthy
HHV-6 (all) 9/200 0/200 13/200 19/200
p = 0.004 p > 0.05
HHV-6B 1/9 0/0 11/13 18/19
HHV-6A 8/9 0/0 2/13 1/19
p = 0.0015
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0.2-3% [19-21]. Individuals with CIHHV-6 have signifi-
cant viral load, over million of GEq/mL blood; infection
or reactivation usually results in only tens of thousands
GEq/mL. It is also suggested that finding of variant A
indicates CIHHV-6 rather then active infection [20,22].
CIHHV-6 can also be reactivated and cells harbouring
CIHHV-6 will produce infectious viral particles [23,24].
In this study, the viral load detected in the blood samples
of the renal transplant patients were in accordance with
average DNA load of active HHV-6 infections.
Contrary to some previous publications [17,25-27],
HHV-6A viraemia was found to be more frequent (eight
out of nine HHV-6 positive samples) in renal transplant
individuals then HHV-6 variant B. Nowadays, effective
immunosuppressive protocols with new drugs result in
improved survival of grafts in organ transplant patients.
However, owing to the strong immunosuppression infec-
tion and consequently hospitalization is increasing among
renal transplant patients [4]. Nearly all of the symptomatic
primary HHV-6 infections in children are caused by var-
iant B, and HHV-6B is detected predominantly in healthy
individuals. HHV-6A has been identified rarely, but often
in severe inflammatory and neurological diseases especially
in immunosuppressed patients [28]. HHV-6A dominance
was observed in human immunodeficiency virus infected
i n d i v i d u a l s ,a n di tm a yf o s t er the progression of AIDS
[11]. HHV-6A may be an emerging pathogen, and strong
immunosuppression of transplant patients might result in
higher frequency of HHV-6A infection. In our study, the
prevalence of latent HHV-6 infection was not significantly
different between renal transplant patients and healthy
blood donors (13/200 vs. 19/200; p > 0.05). Dominance of
variant B was observed in transplant patients (11/13) and
also in healthy blood donors (18/19 latency). The fre-
quency of variant A was significantly higher in viraemia
then in latency in renal transplant patients (8/9 vs. 2/13;
p = 0.0015). HHV-6 variant A can result from latency, pri-
mary infection or reinfection.
Statistical analysis did not find interaction between
HHV-6 viraemia and clinical symptoms in our study. All
of the patients with HHV-6 viraemia had mild diseases at
the time of sample taking, but most of the patients with-
out HHV-6 infection or with latency also had (9/9 vs.
160/191; p > 0.05). Nevertheless, it was not a follow up
study, and we have no data before and after the observed
HHV-6 viraemia.
HHV-6 and HCMV viraemia was not observed simul-
taneously in renal transplant patients, which does not
exclude the interaction between these viruses.
Conclusions
In this study HHV-6 viraemia was detected early and
late after renal transplantation. In contrast to previous
reports, HHV-6 variant A viraemia was found to be pre-
dominant in these patients. Frequency of variant A was
significantly higher in immunocompromised patients
with active infection then with latency. A follow up
study of renal transplant patients may reveal the clinical
importance of HHV-6A and its potential pathogenetical
role.
Methods
Patients and samples
Two hundred EDTA blood samples from 200 renal
transplant patients (114 men, 86 women, median age
45.5, range 11.2-68.8 years) were taken at different times
after transplantation (median 1271 days, range 3-7115
days). The pre-transplant HHV-6 serostatus of the
patients was not determined. Calcineurin inhibitor, ster-
oid and mycophenolate mofetil was used according to
standard immunosuppressive protocols of patients.
Two hundred EDTA blood samples from 200 healthy
blood donors were also collected (75 men, 125 women,
median age 39, range 10-74 years).
Regional and Institutional Ethics Committee of Uni-
versity of Debrecen approved all of the studies. All
patients gave their written informed consent.
Table 2 Clinical data of 200 renal transplant patients
Number of patients
HHV-6+ HHV-6- HCMV+ HCMV-
Respiratory symptoms 27 837 7
Respiratory symptoms with fever 55 315 7
Respiratory and gastrointestinal symptoms 1102
Gastrointestinal symptoms 11 029
Gastrointestinal symptoms with fever 0606
Fever 01 201 2
No clinical symptoms 03 113 0
Total 9 191 7 193
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Nucleic acid from white blood cells (WBC) (1.5 × 10
6
cells/blood sample) and 200 μL plasma (centrifuged for
10 min at 180 × g at 4°C) was isolated by High Pure
Viral Nucleic Acid Kit (Roche, Switzerland) according to
the manufacturer’s instructions. Nucleic acid was eluted
in 50 μL and stored at -20°C until usage.
Variant-specific nested PCR amplification of HHV-6
DNA was performed in a final volume of 20 μL contain-
ing 5 μL DNA solutions as described previously [29].
To distinguish between latent and active HHV-6 infec-
tion, reverse transcription PCR (RT-PCR) was used as
described previously [30].
The effectiveness of DNA and RNA isolation were
controlled by use of PCR and RT-PCR amplification of
b-globin DNA and GAPDH mRNA.
Absolute quantification of HHV-6 DNA using real-
time PCR was performed following the method of Bou-
tolleau et al [31]. For calibration curve plasmid DNA
(pGL2-Basic vector, Promega, USA) containing HHV-6
insert was used.
HCMV pp65 antigenaemia
HCMV reactivation was examined by pp65-antigenae-
mia using CINAkit (Argene, France) according to the
manufacturer’s instructions.
Statistical analysis
Chi sqare test and Fisher’s exact test were used to asses
the difference in frequency for categorical variables.
Mann-Whitney U test was applied for continuous vari-
ables. Difference was considered significant if p value
was less then 0.05.
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